Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Engineering Quiescent Viral Entry Pathways for in Vivo CAR-T Generation via Binder-Fusogen Combinatorics

Xiaoling Wang, wancheng yang, Kaiyuan Wang et al. Nov 03, 2025 pp. 2404-2404 10.1182/blood-2025-2404

Abstract Background: In vivo delivery of CAR constructs via lentiviral vectors is hindered by a critical limitation: conventional viral enve...

Six versus eight doses of rituximab in combination with six cycles of CHOP chemotherapy in patients with previously untreated diffuse large b-cell lymphoma

Yoshimasa Kamoda, Futoshi Iioka, Masako Hirao et al. Nov 03, 2025 pp. 2708-2708 10.1182/blood-2025-2708

Abstract BACKGROUND Six cycles of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) are the standard first-...

Results of the promise study from ~30,000 individuals screened for monoclonal gammopathies

Sabine Allam, Sungjae Kim, Jean-Baptiste Alberge et al. Nov 03, 2025 pp. 403-403 10.1182/blood-2025-403

Abstract Background Monoclonal gammopathy (MG) of undetermined significance (MGUS) affects 3–5% of individuals aged 50 and older, as reporte...

A retrospective Study of pola-R-CHP regimen in treatment-naive patients with diffuse large B-cell lymphoma from northeast China

Shu Zhao, Wenhui Zhao, Lintao Bi et al. Nov 03, 2025 pp. 7211-7211 10.1182/blood-2025-7211

Abstract Background: Diffuse large B-cell lymphoma (DLBCL) is a clinically and molecularly heterogeneous subtype of non-Hodgkin lymphoma, ac...

Impact of aspirin use on clinical outcomes in antiphospholipid syndrome patients with arterial thrombosis: A real-world cohort study

Fayaz Khan, Madhu Bhargavi Chandra, Zuhair Alam Nov 03, 2025 pp. 952-952 10.1182/blood-2025-952

Abstract Background: Antiphospholipid syndrome (APS) is a major cause of arterial thrombosis and recurrent vascular events, often requiring...

Real-world patterns of secondary malignancies and relapse following CAR T-cell therapy: A faers pharmacovigilance analysis

Sheilabi Seeburun, Mohamad Cherry Nov 03, 2025 pp. 7669-7669 10.1182/blood-2025-7669

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapies have transformed the therapeutic landscape for relapsed or refractory...

Elimination of alloantibody responses using chimeric HLA-II antibody receptor T cells

Georgia Papadaki, Huiwu Zhao, Yang Li et al. Nov 03, 2025 pp. 4128-4128 10.1182/blood-2025-4128

Abstract Introduction Anti-HLA antibodies (alloantibodies) pose challenges in the setting of organ or bone marrow transplantation. The prese...

Temporal trends and geographic variation in mortality from hypertensive diseases with coexisting aplastic and other anemias in the United States (1999–2023): A CDC wonder analysis

Mirza Baig, Ibrahim Manzoor, Sravani Bhavanam et al. Nov 03, 2025 pp. 7904-7904 10.1182/blood-2025-7904

Abstract Introduction: Hypertensive disease (HD) refers to a constellation of changes in heart resulting from chronic el...

CDCP1+ mesenchymal stem cells preferentially inhibit acute graft-versus-host disease(aGVHD)

Lun Yan, Jing Li, Xi Zhang et al. Nov 03, 2025 pp. 2466-2466 10.1182/blood-2025-2466

Abstract Object The main complication after hematopoietic stem cells is acute graft-versus-host disease(aGVHD), which affects the success of...

Risk factors for CRS and NT with bispecific antibodies: Data from the American bispecifics and CART (ABC) consortium

Victoria Gill, Ari Pelcovits, Thomas Ollila et al. Nov 03, 2025 pp. 960-960 10.1182/blood-2025-960

Abstract Background: Bispecific antibodies (BsAbs) have changed the treatment paradigm in aggressive B-cell lymphomas, but these agents carr...

Thrombotic risk with thrombopoietin receptor agonists in immune thrombocytopenia: Real-world evidence from a multicenter Japanese study.

Masahiro Yoshida, Satoshi Iyama, Hiroto Horiguchi et al. Nov 03, 2025 pp. 1259-1259 10.1182/blood-2025-1259

Abstract Background: Thrombopoietin receptor agonists (TPO-RAs), which are widely used as second-line or later treatments for immune thrombo...

Real world outcome of nodal T cell non-Hodgkin lymphoma from hematology cancer consortium registry in India

Sreeraj Vasudevan, Anu Korula, Lingaraj Nayak et al. Nov 03, 2025 pp. 7154-7154 10.1182/blood-2025-7154

Abstract Introduction Here we present the real-world outcome of nodal T-NHL data from a prospectively maintained lymphoma registry in India...

Risk of serious bleeding with concomitant use of apixaban or rivaroxaban with amiodarone compared to flecainide or sotalol in patients with atrial fibrillation

Ghadeer Dawwas, Carlos Grijalva Nov 03, 2025 pp. 3136-3136 10.1182/blood-2025-3136

Abstract BACKGROUND Direct oral anticoagulants (DOACs), including apixaban and rivaroxaban, are widely used for stroke prevention in patients...

Clinical characteristics and prognosis of therapy-related hematological neoplasms: A single-center retrospective study

Xiao-Ling Guo, Ming-Li Wang, Zi-Yuan Nie et al. Nov 03, 2025 pp. 6897-6897 10.1182/blood-2025-6897

Abstract Objective: With expanding treatment modalities for solid and hematologic malignancies leading to improved patient survival, the inc...

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Michael Wang, Jonathon Cohen, Nirav Shah et al. Nov 03, 2025 pp. 665-665 10.1182/blood-2025-665

Abstract Background: Despite the efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKi) in R/R MCL, patients (pt...

Complex cytogenetics in myeloid malignancies: A deconstruction analysis redefining complex karyotypes

Alex Bataller, Alexandre Bazinet, Guillermo Montalban-Bravo et al. Nov 03, 2025 pp. 5641-5641 10.1182/blood-2025-5641

Abstract Background: In myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), a complex karyotype (CK) is defined as ³3 unrelate...

Platelet mTOR is a regulator of sterile immunothrombosis

Irina Portier, Frederik Denorme, Heide Castro et al. Nov 03, 2025 pp. 3026-3026 10.1182/blood-2025-3026

Abstract Background: Immunothrombosis entails a tight interplay between thrombotic and inflammatory pathways and plays a pathological role i...

Rapid immune reconstitution in patients with transfusion-dependent thalassemia following betibeglogene autotemcel: A real-world experience

Benjamin Philipson, Jonathan Tedesco, Rheanna Congdon et al. Nov 03, 2025 pp. 4442-4442 10.1182/blood-2025-4442

Abstract Introduction: Gene therapies for transfusion-dependent thalassemia (TDT) such as betibeglogene autotemcel (beti-cel) alleviate tran...

Unmasking PNH: Epidemiological and clinical insights from Qatar

Amna Gameil, Suhair El ajez, Omnya Abdalla et al. Nov 03, 2025 pp. 6722-6722 10.1182/blood-2025-6722

Abstract background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired clonal stem cell disorder caused by somatic mutations in t...

Disparate post-relapse survival outcomes by race/ethnicity for children with B-cell acute lymphoblastic leukemia: An analysis from the recall-1 study

Abigale Berry, Caitlin Elgarten, Yimei Li et al. Nov 03, 2025 pp. 4525-4525 10.1182/blood-2025-4525

Abstract Introduction Pronounced disparities in pediatric B-lymphoblastic leukemia (B-ALL) outcomes by race and ethnicity persist in the con...

Analysis of seasonal variation of sickle cell disease with crisis and associated complication in the United States from 2011 to 2019.

Emeka Agudile, Zeeshan Solangi, Amirta Devi et al. Nov 03, 2025 pp. 7883-7883 10.1182/blood-2025-7883

Abstract Introduction: While the clinical burden of sickle cell disease (SCD) is well recognized, observations suggests that environmental f...

Real-world incidence and management of non-icans neurologic events following ciltacabtagene autoleucel in multiple myeloma

Doris Hansen, Omar Alexis Castaneda Puglianini, Ariel Grajales-Cruz et al. Nov 03, 2025 pp. 4596-4596 10.1182/blood-2025-4596

Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) is an established effective treatment strategy for relapsed/refractory multiple...

Disease presentation and immunophenotype characteristics in 257 patients with blastic plasmacytoid dendritic cell neoplasm: A pethema/PALG study

Beatriz Martín Herreros, Irene Navarro Vicente, Milena Sitkiewicz et al. Nov 03, 2025 pp. 218-218 10.1182/blood-2025-218

Abstract Background Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy characterized by a...

Comparison of real-world survival outcomes and time toxicity of CAR T-cell versus bispecific antibody therapies in relapsed/refractory follicular lymphoma: A multicenter cohort from 15 US academic institutions

Ajay Major, Diana Abbott, Jordan Snyder et al. Nov 03, 2025 pp. 1798-1798 10.1182/blood-2025-1798

Abstract Background Chimeric antigen receptor T-cell (CAR-T) and bispecific antibody (BsAb) therapies are both effective...

Development of NOG-W41-based humanized mouse model for studying In Vivo human hematopoiesis

Ryoji Ito, Yusuke Ohno, Motohito Goto et al. Nov 03, 2025 pp. 4930-4930 10.1182/blood-2025-4930

Abstract Humanized mouse models engrafted with human CD34⁺ hematopoietic stem cells (HSCs) are essential tools for studying human hematopoie...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page